Research programme: small molecule therapeutics - Dianomi Therapeutics
Latest Information Update: 28 Mar 2023
At a glance
- Originator Dianomi Therapeutics
- Class Analgesics; Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis; Pain
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Osteoarthritis in USA
- 28 Mar 2023 No recent reports of development identified for research development in Pain in USA
- 05 Feb 2019 Dianomi Therapeutics in-licenses Mineral Coated Microparticle (MCM) technology from Wisconsin Alumni Research Foundation prior to February 2019